“I think if everyone could consciously do one good deed a day (it’s contagious) then the world would be a better place. If all companies had the goal toward positive social impact, we would be doing business for the right reason and not just for financial gain. I think companies would be surprised how much more financially beneficial it would be if fiscal gain wasn’t their primary goal.”
I had the pleasure of interviewing Robert Davidson. Robert Davidson is CURE’s CEO and Chairman of the Board of Directors. Prior to his role at CURE Pharmaceutical, Davidson served as President and Chief Executive Officer of InnoZen Inc., Chief Executive Officer of Gel Tech LLC, Chief Executive Officer of Bio Delivery Technologies Inc., and has served on multiple corporate boards. Mr. Davidson was responsible for the development of several drug delivery technologies and commercial brand extensions. He has a Masters Certificate in Applied Project Management from Villanova University, Masters of Public Health from American Military University, Virginia and a Masters in Health and Wellness from Liberty University, Virginia. Davidson also completed his Post Graduate Studies at the University of Cambridge with letter of commendation.
I have always been passionate about healthcare and patient access to the best treatment’s regimens possible. A good friend of mine in 2010 piqued my interest in the potential of cannabis and the endocannabinoid system. His dad was suffering from stage four colon cancer, and traditional treatments were wreaking havoc on his body. My friend started researching the use of cannabis as complementary medicine with the traditional chemotherapy approach. He decided he had nothing to lose and started giving his dad cannabis oil under the tongue. To his surprise, his dad during his second round of chemo gained all of his weight back and responded positively to the chemotherapy. By the end of the second treatment, his dad went into full remission. I started hearing similar stories by nurses and doctors from several different hospitals in California. Needless to say, my interest was piqued.
CURE is a fully integrated FDA, and DEA registered manufacturing facility. When CURE first announced its entry into the cannabinoid space through research that we were conducting on certain types of cancer with Technion Institute in Israel, we had a plethora of individuals reaching out to us asking for samples. It was such a visceral experience to hear from so many people desperate for a better way to treat cancer. It was difficult to have to tell them that we did not have product yet as we are still in early-stage research.
I think as much as we try to mitigate mistakes during the start of a business they are inevitable. In fact, I think mistakes are what help startups propel themselves to success if (and big if here) they can learn from them. One day I was giving a tour of the CURE facility to a group that was interested in learning about some of our pharmaceutical applications and the potential positive social impact it would have on the target patient populations. As we were touring the facility, I stopped and picked up some samples from the packaging line, and it just happened to be Sildenafil a generic form of Viagra. One of the members of the tour smiled and asked what positive impact would that have on patients? I struggled to answer his question, but a few seconds later I smiled back and said we are keeping couples together. The lesson — make sure you know what you are showing before you show it and know the audience you are showing it to.
Yes, we have several great products and research we are working on. We have a partnership with Canopy Growth, a leading international cannabis company. We are the exclusive OTF delivery technology and are developing dosage forms for their proprietary extracts. We just received schedule 1 DEA approval for manufacturing and research of Cannabinoid molecules. This license will allow us to duplicate research that we are doing in Canada and Israel right here at our facility in Oxnard, CA USA.
I don’t think there is one person that helps you achieve success. I think we interact with so many people in our lives that all have an impact on us one way or another. I’m thankful for everyone that I have met over the years whether it was for a few seconds or a few years. Each one of them has had some influence, either consciously or subconsciously, on my thought process and approach to life.
Since we are a federally regulated pharmaceutical company, we are still early-stage in our product development. So, we don’t do a lot of marketing. At this point, we are more focused on trying to bring understanding and clarity to the industry through earned media opportunities, speaking engagements and writing bylines, guest op-eds and articles that help demystify the cannabinoid research and oral thin films industry. The medical cannabis industry still faces many barriers and challenges due to the stigma surrounding it. We’re working to change that.
I believe that treatments based on the endocannabinoid system are the new frontier of medicine. The opening up of regulations for researching cannabis molecules on the cannabinoid system is extremely exciting to us. I think that the cannabis movement is responsible for a push towards personalized medicine instead of one size fits all. At CURE, we agree that personalized medicine is the way of the future. My concerns are directly related to companies that are selling formulations with no real research to support the efficacy of the different indications. The potential for oils tainted with pesticides and microbes due to the lack of regulations in certain states and non-precise dosing is concerning and has the potential to damage the reputation of the entire industry.
I think that drug delivery, testing and supply chain management are areas that will have strong growth in the next few years. These are the three areas that have the largest unmet needs.
Don’t take them for granted. Without employees, you don’t have a company. It’s that simple. You followed a dream to get to where you are at, let your employees dream with you. Don’t micromanage. Instead, let them feel a part of the process. Give them the tools they need to be successful and get out of the way. At CURE, every employee owns shares. Listen to their ideas and comments; often their suggestions make a big difference.
I think if everyone could consciously do one good deed a day (it’s contagious) then the world would be a better place. If all companies had the goal toward positive social impact, we would be doing business for the right reason and not just for financial gain. I think companies would be surprised how much more financially beneficial it would be if fiscal gain wasn’t their primary goal.
· @Cure_Pharma_: https://twitter.com/cure_pharma_
· @RobDavidson20: https://twitter.com/RobDavidson20
About the author:
Len Giancola has over 25 years of experience in Executive Management and Business Ownership. Formerly a Managing Director of Global Securities Finance in New York, responsible for a $16 billion trading portfolio, he is now an Officer/Board Member of over 30 corporations. With well over $100 million in sales over the last decade, including a successful residential development company, vacation rental property management company and diversified investment and online technology portfolio, Len is a Founding Partner of MJ.com and is a frequent media guest on international podcasts such as Rich Dad Radio with Robert Kiyosaki along with many other entrepreneurial and mentorship vehicles.